Guardian Pharmacy Services stock
GRDNNYSEGuardian Pharmacy Services, Inc., HealthcareISIN US40145W1018
77Score 77 out of 100, Strong
Price and trend
81 / 100
Price history
+57% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 27% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 78).
The price is 1.2% below its 52-week high. Largest decline in 2 years: 27% (December 2024 to March 2025).
Chart figures for advanced users
- SMA 50$42.29
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$38.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)78
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$27.03
- The lowest closing price of the last twelve months.
- Resistance$49.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Guardian Pharmacy Services, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $3.13B, is number 24 of 57 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $1.44B (down 0.4%) and adjusted earnings per share of $1.30 (up 22.8%).
- MEQIRI Score 77 out of 100 (Strong): rank 41 of 702 in Healthcare, median 53.
Show more
- The P/E is 42.2 (Medical (Care Facilities) median 19.6, own median of recent years 38.1).
- Our model puts fair value at $24.57, with the price 101% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 32.5% in fiscal 2025, Medical (Care Facilities) median 6.1%.Profitability 68
- Earnings per share growingUp 19.1% a year since 2020.Growth 87
- Growing faster than its industryRevenue up 14.5% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 87
Weaknesses
- Above fair valuePrice 101% above the fair value of $24.57.Valuation 23
Its standout strengths are momentum and fundamentals, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
- price up very strongly over the past year
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $17.55 and expensive above $40.95 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $26.16 (cash-flow model) and $22.98 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $22.57, at 7.8% it would be $27.55.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.9% on the twelve months before. Revenue has grown strongly since 2018, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 19%, operating 6%, net 3%.
Debt & balance sheet
Fiscal 2025The balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Mar 2027in 117 days
- Last reported
- 5 Nov 2026EPS reported $0.33 (expected $0.31)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.300.0%
- Revenue
- $1.44B0.0%
- Earnings per share
- $1.430.0%
- Revenue
- $1.53B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +8.2%2026 guidance raised: revenue of $1.43 billion to $1.45 billion (previously $1.40 billion to $1.42 billion) and adjusted EBITDA of $129 million to $131 million.
“We now expect revenue of $1.43 billion to $1.45 billion and adjusted EBITDA of $129 million to $131 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Morris David KSale
20 Mar 2026, See Remarks
- Shares
- 187,855
- Price
- $29.68
- Value
- $5.58M
- Burke FredSale
20 Mar 2026, See Remarks
- Shares
- 671,432
- Price
- $29.68
- Value
- $19.93M
- Forbes KendallSale
20 Mar 2026, See Remarks
- Shares
- 346,672
- Price
- $29.68
- Value
- $10.29M
Show 4 more
- Ackerman John, Pharmacy Investors, LLCSale
20 Mar 2026, Board
- Shares
- 827,636
- Price
- $29.68
- Value
- $24.57M
- Ackerman John, Cardinal Equity Fund, L.P.Sale
20 Mar 2026, Board
- Shares
- 275,728
- Price
- $29.68
- Value
- $8.18M
- Bindley William E, Salentine Thomas J Jr, Bindley Capital Partners I, LLCSale
20 Mar 2026, Board
- Shares
- 3,570,677
- Price
- $29.68
- Value
- $105.99M
- Cosler Steven DPurchase
3 Dec 2025, Board
- Shares
- 3,370
- Price
- $29.61
- Value
- $99,786
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Guardian Pharmacy Services
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 77
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- MedicoverMCOV-B.ST $4.01B61
- Acadia HealthcareACHC $3.52B48
- Surgery PartnersSGRY $3.48B53
- National HealthCareNHC $3.3B68
- Aveanna Healthcare HoldingsAVAH $2.67B60
- Ardent HealthARDT $2.49B60
- Pediatrix Medical GroupMD $2.45B70
- Addus HomeCareADUS $2.31B70
ETFs that hold Guardian Pharmacy Services
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.5B |
Show 3 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €964.08M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 13 Mar 2026)
- Valuation signal Overvalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.